KLACID XL Tablets / Modified Release
Clarithromycin
500mg
ABBOTT LABORATORIES LIMITED
| Pack size | 7's Blister |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | CITY MEDICAL STORE |
| Retail Price | 47.50 AED |
Available as:
Indications
KLACID XL Tablets / Modified Release is used for:
Respiratory tract infections, Skin and soft tissue infections, Leprosy, peptic ulcer disease, pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia, legionellosis, Helicobacter pylori, lyme disease, Community-Acquired Pneumonia.
Adult Dose
Oral
Acute Exacerbation of Chronic Bronchitis
250-500 mg PO q12hr for 7-14 days
Extended release: 1000 mg PO once daily for 7 days
Mycobacterial Infection
Prophylaxis and treatment
500 mg PO q12hr for 7-14 days
Use with antimycobacterial drugs such as rifampin and ethambutol
Peptic Ulcer Disease
500 mg PO q8-12hr for 10-14 days
Administer as part of 2- or 3-drug combination regimen with bismuth subsalicylate, amoxicillin, H2 receptor antagonist, or proton pump inhibitor
Pharyngitis, Tonsillitis
250 mg PO q12hr for 10 days
Community-Acquired Pneumonia, Skin/Skin Structure Infection
250 mg PO q12hr for 7-14 days
Extended release: 1000 mg PO once daily for 7 days
Endocarditis
Prophylaxis
500 mg PO 30-60 minutes before surgical procedure
Intravenous
Respiratory tract infections; Skin and soft tissue infections ; Susceptible infections
Adult: 500 mg bid for 2-5 days. Infuse over 60 min using a 0.2% soln. Revert to oral therapy whenever possible.
Child Dose
Child: PO 15 mg/kg/day, max 1 g/day q12h
Renal Dose
Renal impairment:
CrCl (ml/min)
<30 Half the dosage or double dosing interval.
Administration
Standard release tab & oral susp: May be taken with or without food.
XL & MR tab: Should be taken with food. Swallow whole, do not chew/crush.
Contra Indications
Hypersensitivity. Patients receiving terfenadine, astemizole, pimozide, cisapride and ergot derivatives. Pregnancy; history of acute porphyria.
Precautions
Renal and hepatic impairment; macrolide cross-resistance; lactation, children.
Lactation: Drug is excreted in breast milk; use with caution
Pregnancy-Lactation
Pregnancy Category: B
Lactation: enters breast milk/not recommended
Interactions
Reduced efficacy w/ CYP3A inducers (e.g. phenytoin, carbamazepine). Strong inducers of CYP450 system (e.g. efavirenz, rifampicin) may accelerate metabolism, thus lower plasma levels of clarithromycin. Inhibition of metabolism w/ ritonavir. Torsades de pointes may result from concomitant quinidine or disopyramide. Increased phosphodiesterase inhibitor exposure w/ sildenafil, tadalafil or vardenafil. Increased risk of digoxin toxicity. Decreased concentration of zidovudine.
Concomitant use w/ atazanavir, itraconazole or saquinavir may result to bi-directional drug interactions. Hypotension, bradyarrhythmias, and lactic acidosis may result when taken w/ verapamil. Increased risk of myopathy, including rhabdomyolysis w/ HMG-CoA reductase inhibitors. Increased risk of hypoglycaemia w/ oral hypoglycaemic drugs (e.g. pioglitazone) and insulin. Risk of serious haemorrhage and elevation of INR and prothrombin time w/ oral anticoagulants. Increased ototoxicity w/ aminoglycosides. Increased and prolonged sedation w/ triabenzodiazepines (e.g. midazolam).
Potentially Fatal: Concurrent use w/ ergot alkaloids (e.g. ergotamine or dihydroergotamine) is associated w/ acute ergot toxicity characterised by vasospasm and ischaemia of the extremities. Concomitant use w/ astemizole, cisapride, pimozide and terfenadine may result in QT prolongation or ventricular cardiac arrhythmia.
Adverse Effects
Side effects of Clarithromycin :
>10%
Gastrointestinal (GI) effects, general (13%)
1-10%
Abnormal taste (adults, 3-7%), Diarrhea (3-6%), Nausea (adults, 3-6%), Vomiting (adults, 1%; children, 6%), Elevated blood urea nitrogen (BUN; 4%), Abdominal pain (adults, 2%; children, 3%), Rash (children, 3%), Dyspepsia (2%), Heartburn (adults, 2%), Headache (2%), Elevated prothrombin time (PT; 1%)
<1%
Anaphylaxis, Anorexia, Anxiety, Clostridium difficile colitis, Dizziness, Dyspnea, Elevated liver function tests, Glossitis, Hallucinations, Hepatic dysfunction, Hepatitis, Hypoglycemia, Increased alkaline phosphatase, Increased aspartate aminotransferase, Increased bilirubin, Increased serum creatinine, Jaundice, Leukopenia, Manic behavior, Neuromuscular blockade, Neutropenia, Pancreatitis, Psychosis, QT prolongation, Seizures, Stevens-Johnson syndrome, Thrombocytopenia
Potentially Fatal: Pseudomembranous colitis, anaphylaxis, Stevens-Johnson syndrome.
Mechanism of Action
Clarithromycin inhibits protein synthesis by binding to 50s ribosomal subunits of susceptible organisms. It has activity against susceptible streptococci and staphylococci as well as other species including B. catarrhalis, L. spp, C. trachomatis and U. urealyticum.
Note
KLACID XL 500mg Tablets / Modified Release manufactured by ABBOTT LABORATORIES LIMITED. Its generic name is Clarithromycin. KLACID XL is availble in United Arab Emirates.
Farmaco UAE drug index information on KLACID XL Tablets / Modified Release is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Clarithromycin :
Suspension
Clamycin
125mg/5ml
Julphar (Gulf Pharmaceutical Industries)
Suspension
Clamycin
250mg/5ml
Julphar (Gulf Pharmaceutical Industries)
Tablets / Film-coated
Spectromax
250mg
National Pharmaceutical industries Co. (SAOG)
Tablets / Film-coated
Spectromax
500mg
National Pharmaceutical industries Co. (SAOG)
Suspension
Klacid
125mg/5ml
ABBOTT S.p.A.